PERS seeking new treatments for conduct disorder in children and adolescents |
|
The Pediatric European Risperidone Studies (PERS) address the topic of the FP7-Health-4.2-1 work program “Adapting off-patent medicines to the specific needs of paediatric populations”. Risperidone, a second-generation antipsychotic, is widely prescribed to children and adolescents in a variety of conditions such as psychotic disorders, externalizing symptoms associated with autism or mental retardation, aggressive behavior in disruptive behavior disorders. The PERS project addresses major gaps in the evidence-base of the use of risperidone for the treatment of conduct disorder in children and adolescents. PERS proposes 3 clinical studies that will provide information on efficacy and tolerability for the use of risperidone in children and adolescents with conduct disorder and long term safety of risperidone in children and adolescents receiving risperidone for a variety of conditions. |
June 27, 2011
ECNP Network initiative: meeting of the child and adolescent network (ECAPN) during the ECNP Congress in Paris, 6 September 17.00 to 18.30 in room 136M.
Read more about the Congress here.
June 17, 2011
Welcome to our brand new site!
We are glad to introduce the PERS project to you. Enjoy reading and feel free to contact us for queries.
June 17, 2011
Consortium Meeting, Paris
Members of the PERS Consortium meet in Paris to discuss latest events, progress and next steps.
© 2011 PERS: Paediatric European Risperidone Studies
 |
The research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement n° 241959. |
